Johnson & Johnson maintains 2025 guidance after beating Q2 expectations
Overview Johnson & Johnson has reaffirmed its full-year guidance after posting stronger-than-expected earnings for Q2 of 2025, driven by solid performance across its Innovative Medicine and MedTech segments. The company reported sales of $23.7bn, marking a 5.8% increase compared to the second quarter of 2024. Net earnings totaled $5.5bn, or $2.29 per share on a…
